Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Eyenovia Inc Market Cap
The Eyenovia Inc (EYEN) share price is expected to increase by 3400% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered EYEN. Price targets range from $2 at the low end to $5 at the high end. The current analyst consensus for EYEN is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
About 3 Wall Street analysts have assigned EYEN 0 buy ratings, 3 hold ratings, and 0 sell ratings. This means that analysts expect Eyenovia Inc to generate similar returns as the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on EYEN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of EYEN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Matthew Kaplan Ladenburg Thalmann | Neutral | Downgrade | Nov 18, 2024 | |
| Matthew Caufield HC Wainwright & Co. | Neutral | $2 | Downgrade | Nov 18, 2024 |
| Kemp Dolliver Brookline Capital | Hold | Downgrade | Nov 15, 2024 | |
| Tim Lugo William Blair | Market Perform | Downgrade | Nov 15, 2024 | |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | Nov 13, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | Aug 13, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | Jul 24, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | May 16, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | Mar 19, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | Mar 6, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | Nov 14, 2023 |
| Tim Lugo William Blair | Outperform | Initiates | Nov 1, 2023 | |
| Kemp Dolliver Brookline Capital | Buy | $8 | Initiates | Oct 17, 2023 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | Aug 18, 2023 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | Aug 11, 2023 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | May 12, 2023 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | Apr 19, 2023 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Reiterates | Apr 3, 2023 |
| Matthew Caufield HC Wainwright & Co. | Buy | $12 | Initiates | Oct 5, 2022 |
| Yi Chen HC Wainwright & Co. | Buy | $8 | Maintains | Apr 1, 2021 |
When did it IPO
2018
Staff Count
57
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Michael M. Rowe
Market Cap
$9.5M
In 2023, EYEN generated $3,787 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that EYEN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 06 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Eyenovia, Inc. announced a registered direct offering with an institutional investor for 20,085,025 shares and warrants for 40,170,050 shares at $0.0969 each. Closing expected by December 9, 2024.
Why It Matters - Eyenovia's direct offering of shares and warrants at $0.0969 indicates a capital raise, potentially diluting existing shares, impacting stock value and market perception.
Fri, 22 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Avenue Capital has agreed to defer the principal and interest payments on the Company’s outstanding debt until the end of February 2025.
Why It Matters - The deferral of principal and interest payments indicates financial distress, potentially impacting the company's cash flow and creditworthiness, which could affect stock prices and investor confidence.
Mon, 18 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - EYEN stock declines sharply after the termination of its late-stage myopia study for MicroPine due to unfavorable feedback from an independent Data Review Committee.
Why It Matters - Termination of the myopia study signals potential setbacks in product development, impacting future revenue and investor confidence in EYEN's growth prospects.
Fri, 15 Nov 2024
Sentiment - NEGATIVE
Source - Reuters
Summary - Eyenovia will terminate a late-stage study on its experimental drug-device for pediatric progressive myopia due to failure to meet the main study goal.
Why It Matters - Eyenovia's decision to terminate the study indicates setbacks in drug development, potentially impacting stock value and investor confidence in future prospects.
Fri, 15 Nov 2024
Sentiment - NEGATIVE
Source - Benzinga
Summary - Eyenovia, Inc. (EYEN) stock declined after an update on the Phase 3 CHAPERONE study for its low-dose atropine drug-device combination in pediatric myopia.
Why It Matters - Eyenovia's stock decline reflects potential setbacks in its Phase 3 study, which may impact future revenue and market confidence in its drug-device product for pediatric myopia.
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The independent Data Review Committee found that the CHAPERONE study is not meeting its primary three-year efficacy endpoint.
Why It Matters - CHAPERONE's failure to meet its primary efficacy endpoint may lead to decreased confidence in its market potential, potentially impacting stock prices and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
